2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
Wojeck BS, Inzucchi SE, Neeland IJ, Mancuso JP, Frederich R, Masiukiewicz U, Cater NB, McGuire DK, Cannon CP, Yaggi HK. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep And Breathing 2022, 27: 669-672. PMID: 35596030, PMCID: PMC10212814, DOI: 10.1007/s11325-022-02594-2.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaIncident obstructive sleep apneaAtherosclerotic CV diseaseVERTIS CVSleep apneaMultivariable Cox proportional hazards regression modelsIncidence of OSACox proportional hazards regression modelBaseline obstructive sleep apneaMajor adverse CV eventsProportional hazards regression modelsCV outcome trialsEffect of ertugliflozinInvestigator-reported eventsVERTIS-CV trialAdverse CV eventsSleep apnea syndromeRelative risk reductionHazards regression modelsType 2 diabetesCV eventsCV diseasePrimary endpointInhibitor empagliflozinOutcome trials
2020
Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial
Yaggi H, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi S, Wanner C, Zwiener I, Wojeck B, Neeland I, Johansen O. Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. European Heart Journal 2020, 41: ehaa946.2883. DOI: 10.1093/ehjci/ehaa946.2883.Peer-Reviewed Original ResearchEMPA-REG OUTCOMECardiovascular diseaseIncidence rateMajor adverse CV eventsPlacebo-controlled outcome trialsAdverse CV eventsGlomerular filtration rateSystolic blood pressureCox regression modelStandard of careType 2 diabetesCV deathCV eventsCV outcomesMultivariable adjustmentInhibitor empagliflozinOutcome trialsBlood pressureHeart failureWaist circumferenceMortality outcomesSodium glucoseFiltration rateMetabolic disturbancesPatients